Physician
Amin's Family Practice Associates , PSC
Amin's Family Practice Associates , PSC was paid $11.12M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 99232, hospital visit by a doctor, follow-up day — 14% of everything it billed.
33Billing provider infoAMIN'S FAMILY PRACTICE ASSOCIATES , PSC
LOUISVILLE, KY 40208
LOUISVILLE, KY 40208
33aNPI1750307393assigned 07/15/2006
33bProvider typeFamily Medicine Physician
28Total paid$11.12M
24GClaims750,535
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Kentucky
Rank by total paid#5 of 352
Median peer was paid$90K
This provider vs. median124×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,484 | $1.60M | |
| 2019 | 68,896 | $1.59M | |
| 2020 | 78,955 | $1.43M | |
| 2021 | 118,719 | $1.36M | |
| 2022 | 149,806 | $1.72M | |
| 2023 | 155,713 | $1.81M | |
| 2024incomplete | 125,962 | $1.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 14% | 58,735 | 11,196 | $1.55M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.7% | 33,698 | 29,188 | $1.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.2% | 43,169 | 36,840 | $1.02M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.8% | 5,346 | 5,004 | $869K |
| 80050 | General health panel | 5.9% | 18,125 | 16,069 | $660K |
| 99490 | Ccm add 20min | 4.4% | 18,337 | 17,562 | $490K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.8% | 10,675 | 9,494 | $421K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 3.7% | 26,512 | 8,504 | $411K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 3.3% | 9,762 | 2,707 | $369K |
| 80061 | Lipid panel | 3.0% | 34,090 | 29,988 | $337K |
| 99239 | Hospital discharge day management, more than 30 minutes | 2.7% | 7,405 | 6,321 | $304K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.7% | 4,387 | 3,971 | $298K |
163 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.6% | 14,087 | $284K |
| 99253 | 2.4% | 4,563 | $272K | |
| 99222 | Initial hospital care, per day, moderate complexity | 2.4% | 5,669 | $268K |
| 99223 | Prolong inpt eval add15 m | 2.1% | 2,920 | $230K |
| 99439 | 1.5% | 6,096 | $163K | |
| 99406 | 1.4% | 26,066 | $153K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 2,039 | $140K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.1% | 2,340 | $127K |
| 99497 | 1.1% | 3,632 | $124K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 22,336 | $119K |
| 80053 | Comprehensive metabolic panel | <1% | 16,355 | $111K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,307 | $108K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 456 | $108K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,311 | $104K |
| 94010 | <1% | 4,151 | $63K | |
| 99221 | <1% | 1,960 | $59K | |
| 82607 | <1% | 5,021 | $52K | |
| 92587 | <1% | 1,771 | $42K | |
| 87631 | <1% | 467 | $42K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,307 | $39K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,277 | $37K |
| 87632 | <1% | 159 | $35K | |
| 99173 | <1% | 1,806 | $35K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 644 | $29K |
| 99408 | <1% | 2,852 | $28K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,092 | $27K |
| 87150 | <1% | 275 | $27K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 1,874 | $26K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 393 | $26K |
| 99385 | <1% | 331 | $21K | |
| 87581 | <1% | 793 | $20K | |
| 87486 | <1% | 795 | $19K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 332 | $19K |
| 81003 | <1% | 15,106 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,822 | $18K |
| 90756 | <1% | 1,289 | $18K | |
| 99252 | <1% | 526 | $17K | |
| 99429 | <1% | 265 | $17K | |
| 99217 | <1% | 770 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,669 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,053 | $15K |
| 99219 | <1% | 430 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 159 | $12K |
| 82044 | <1% | 2,771 | $11K | |
| 84439 | <1% | 1,687 | $11K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 189 | $11K |
| 97802 | <1% | 1,839 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 836 | $10K |
| 86789 | <1% | 669 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 148 | $9K |
| 96127 | <1% | 3,157 | $8K | |
| 81025 | <1% | 1,022 | $7K | |
| 99386 | <1% | 115 | $7K | |
| 82746 | <1% | 550 | $6K | |
| 84480 | <1% | 580 | $6K | |
| 82728 | <1% | 527 | $5K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 757 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 384 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 166 | $4K |
| 87800 | <1% | 90 | $4K | |
| 99251 | <1% | 152 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 164 | $3K |
| 90633 | <1% | 244 | $3K | |
| 90688 | <1% | 483 | $3K | |
| 99218 | <1% | 134 | $3K | |
| 82570 | <1% | 679 | $2K | |
| 99401 | <1% | 983 | $2K | |
| 99225 | <1% | 132 | $2K | |
| 82043 | <1% | 474 | $2K | |
| 90461 | <1% | 204 | $2K | |
| 87500 | <1% | 231 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 47 | $2K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 1,156 | $2K |
| 87481 | <1% | 236 | $2K | |
| 87641 | <1% | 231 | $2K | |
| 87653 | <1% | 231 | $2K | |
| 87640 | <1% | 232 | $2K | |
| 99441 | <1% | 106 | $2K | |
| 82962 | <1% | 516 | $1K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,344 | $1K |
| 85651 | <1% | 343 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 21 | $981.39 |
| 90734 | <1% | 48 | $947.88 | |
| 93000 | <1% | 97 | $852.94 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 58 | $852.59 |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 74 | $816.61 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 140 | $797.56 |
| 3044F | <1% | 6,988 | $754.70 | |
| 99307 | <1% | 60 | $754.57 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 12 | $698.43 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,727 | $683.75 |
| 90651 | <1% | 84 | $673.60 | |
| 0134A | <1% | 32 | $621.70 | |
| 99442 | <1% | 18 | $442.61 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 333 | $392.28 |
| 84436 | <1% | 98 | $325.98 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 72 | $295.74 |
| 99224 | <1% | 17 | $197.32 | |
| 3046F | <1% | 511 | $181.37 | |
| 1125F | <1% | 22,198 | $127.88 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 18 | $89.86 |
| 1159F | <1% | 26,640 | $40.43 | |
| 1160F | <1% | 26,642 | $40.42 | |
| 90686 | <1% | 197 | $39.50 | |
| G0008 | Administration of influenza virus vaccine | <1% | 160 | $35.98 |
| 3074F | <1% | 12,007 | $34.33 | |
| 3078F | <1% | 10,295 | $28.44 | |
| 3008F | <1% | 14,868 | $26.88 | |
| 1170F | <1% | 9,252 | $26.60 | |
| 1036F | <1% | 19,239 | $26.06 | |
| 1034F | <1% | 16,747 | $22.10 | |
| 1126F | <1% | 8,930 | $21.56 | |
| 3077F | <1% | 7,627 | $16.07 | |
| 3079F | <1% | 6,137 | $15.29 | |
| 3080F | <1% | 6,391 | $15.16 | |
| 2010F | <1% | 8,080 | $14.00 | |
| 1101F | <1% | 9,258 | $11.94 | |
| 3075F | <1% | 3,426 | $8.66 | |
| 2014F | <1% | 3,077 | $6.48 | |
| 1158F | <1% | 3,684 | $3.68 | |
| 3023F | <1% | 243 | $1.63 | |
| 0521F | <1% | 1,361 | $1.02 | |
| 3014F | <1% | 284 | $1.01 | |
| 3017F | <1% | 264 | $0.80 | |
| 3051F | <1% | 185 | $0.76 | |
| 3060F | <1% | 741 | $0.32 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 2,364 | $0.31 |
| 3066F | <1% | 39 | $0.13 | |
| 1000F | <1% | 5,664 | $0.05 | |
| 2001F | <1% | 1,698 | $0.04 | |
| 2000F | <1% | 2,493 | $0.02 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | <1% | 864 | $0.02 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 407 | $0.01 |
| 2035F | <1% | 1,276 | $0.01 | |
| 91313 | <1% | 32 | $0.01 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 3,113 | $0.01 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 1,533 | $0.01 |
| 3725F | 0% | 5,402 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 768 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,419 | $0.00 |
| 4004F | 0% | 2,326 | $0.00 | |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 52 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 142 | $0.00 |
| 3288F | 0% | 128 | $0.00 | |
| 90662 | 0% | 34 | $0.00 | |
| G8511 | Screening for depression documented as positive, follow-up plan not documented, reason not given | 0% | 46 | $0.00 |
| 90715 | 0% | 14 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 13 | $0.00 |
| G8482 | Influenza immunization administered or previously received | 0% | 18 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 1,056 | $0.00 |
| 1055F | 0% | 1,527 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 175 | $0.00 |
| 4037F | 0% | 287 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 153 | $0.00 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 904 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 131 | $0.00 |
| 1157F | 0% | 127 | $0.00 | |
| 3037F | 0% | 1,039 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 74 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 37 | $0.00 |
| 3061F | 0% | 87 | $0.00 | |
| 4000F | 0% | 120 | $0.00 | |
| 90619 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAMIN, RAJAN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Lakeland Alf Management, LLC | Lakeland, FL | $3.30M |
| Haines Alf Management, LLC | Haines City, FL | $3.15M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.